Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: Evaluation of sustained release and accumulation nature

Hepato-Gastroenterology

Volumn 55, Issue 81, 2008, Pages 202-206

  Takaki, Yasunobu ^a,d   Kaminou, Toshio ^a   Shabana, Masanobu ^b   Ihaya, Takashi ^c   Otsubo, Kenji ^a   Ogawa, Toshihide ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b Matsue City Hospital   (Japan)

^c SAN IN ROSAI HOSPITAL   (Japan)

^d TOTTORI UNIVERSITY   (Japan)

Author keywords

Cisplatin; Emulsion; Hepatocellular carcinoma; Lipiodol; Suspension; Suspension emulsion; Transcatheter arterial chemoembolization

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; CONTRAST MEDIUM; IODINATED POPPYSEED OIL;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANOREXIA; ARTICLE; BILE DUCT INJURY; BLOOD TOXICITY; CANCER DIAGNOSIS; CANCER THERAPY; CHEMOEMBOLIZATION; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG SCREENING; EMULSION; FEMALE; FEVER; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; CONTRAST MEDIA; EMULSIONS; FEMALE; HUMANS; IODIZED OIL; LIVER NEOPLASMS; MALE; MIDDLE AGED; SUSPENSIONS;

EID: 41549153267     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ikai I, Arii S, Ichida T, et al: Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005; 32(3):163-172.
2. Sasaki Y, Imaoka S, Kasugai H, et al: A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 1987; 60(6):1194-1203.
3. Solomon B, Soulen MC, Baum RA, et al: Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, ethiodol, and polyvinyl alcohol: prospective evaluation of response and survival in a U.S. population. J Vasc Interv Radiol 1999; 10(6):793-798.
4. Konno T, Maeda H, Iwai K, et al: Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983; 19(8):1053-1065.
5. Loehrer PJ, Einhorn LH: Drugs five years later. Cisplatin. Ann Intern Med 1984; 100(5):704-713.
6. Melia WM, Westaby D, Williams R: Diamminodichloride platinum (cis-platinum) in the treatment of hepatocellular carcinoma. Clin Oncol 1981; 7(4):275-280.
7. Ikeda M, Maeda S, Shibata J, et al: Transcatheter arterial chemotherapy with and without embolization in patients with hepatocellular carcinoma. Oncology 2004; 66(1):24-31.
8. Maeda S, Shibata J, Fujiyama S, et al: Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepatogastroenterology 2003; 50(51):809-813.
9. Shibata J, Fujiyama S, Sato T, et al: Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989; 64(8):1586-1594.
10. Yamamoto K, Shimizu T, Narabayashi I: Intraarterial infusion chemotherapy with lipiodol-CDDP suspension for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2000; 23(1):26-39.
11. Yamashita Y, Nakagawa N, Miyawaki M et al: Experimental study of hepatic arterial embolization therapy by various formulations of anticanceragent-Lipipodol. Nippon Acta Radiol 1985; 45:1313-1321. (In Japanese with English abstract)
12. Kamada K, Nakanishi T, Kitamoto M, et al: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 2001; 12(7):847-854.
13. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5):116411-116471.
14. Nakashima M, Nakano M, Ishii Y, et al: Tissue distribution of cisplatin after hepatic arterial injection of a cisplatin-lipiodol suspension containing phosphatidylcholine to rabbits carrying VX-2 hepatic carcinoma. Pharm Res 1989; 6(4):342-345.
15. Masuda M, et al: Evaluation of basic and clinical study on effect of anticancer drugs of Lipiodol in chemoembolization on liver tissue. J Wakayama Med Soc 2002; 53(3):185-192. (In Japanese with English abstract)
16. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332(19):1256-1261.
17. Pelletier G, Ducreux M, Gay F, et al: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol 1998; 29(1):129-134.